Get Involved
About Us
Our Members
Turmeric Patent Overturned in Legal Victory.
India's successful challenging of a U.S. patent (No. 5,401,504) on the use of turmeric (Curcuma longa L., Zingiberaceae) for healing has been an encouraging victory for Indian activists campaigning to protect indigenous wisdom.

After a complex legal battle, the U.S. Patents and Trademarks Office ruled on Aug. 14 that a patent for turmeric issued to the University of Mississippi Medical Center in December 1993 was invalid because it was not a novel invention.

The patent was contested by India's Council for Scientific and Industrial Research (CSIR), which combined scientific evidence with legal savvy to take on the biopirates. Says an excited R. A. Mashelkar, director-general of the CSIR, "This success will enhance the confidence of the people and help remove fears about India's helplessness on preventing bio-piracy and appropriation of inventions based on traditional knowledge."

The turmeric patent was just one of the hundreds that the North has claimed by ignoring indigenous and existing knowledge. Vandana Shiva, a global campaigner for a fair and honest Intellectual Property Rights system, says patents on Neem, Amla, Jar Amla, Anar, Salai, Dudhi, Gulmendhi, Bagbherenda, Karela, Erand, Rangoon-kibel, Vilayetishisham and Chamkura need to be revoked.

This can be done if laws are changed to ensure protection against bio-piracy, activists say, because "chasing every patent based on traditional knowledge will involve huge expenses and efforts," according to farm scientist Devinder Sharma.

Under World Trade Organisation (WTO) rules, patents are provided for inventions that qualify for their novelty, non-obviousness, and utility. The turmeric patent failed to satisfy the criteria of novelty as turmeric paste has been used to treat wounds and stomach infections for centuries by Indians.

It is the WTO which has to protect indigenous knowledge, argues Sharma, who says, "governments of developing countries cannot chase and challenge every indigenous knowledge-based product patent. Patent laws need to be changed, the onus of proof reversed and companies should give an undertaking that the patent they are seeking is not based on traditional wisdom."

Suman Sahai of the New Delhi-based Gene Campaign would like the government to use the turmeric case to "press the North to reform its own laws governing intellectual property rights, instead of pressuring the South to change its laws."

Vandana Shiva points out that "examples of bio-piracy make it clear that it is not just Indian patent laws that need to be changed. The American laws also need to be changed to fit into a fair and honest global Intellectual Property Rights system."

To prove her point, she cites the case of Thailand, which prepared a draft legislation allowing Thai healers to register traditional medicines. But it was challenged by the U.S. Department of State, which said, "such a registration system could constitute a possible violation of TRIPS (Trade-Related Intellectual Property Rights) and hamper medical research into these compounds."

"If we get a ruling in our favour, the problem of bio-piracy will be solved. If the WTO does not respond, it will show the WTO's bias towards the powerful countries," Shiva wrote in The Hindu newspaper.

Because two-thirds of the world's plant species -- at least 35,000 of which are estimated to have medicinal value -- are in the developing countries, the North is determined to keep its business edge over the South.

The U.S. is more obsessed with getting India to comply with the TRIPs Agreement. The reason for this, according to Sharma, is to protect the U.S. biotechnology industry from sharing the benefits with countries from which they draw the plant and animal genetic resources.

This contravenes the Convention on Biological Diversity, but the U.S. has made it clear that it has no intentions of abiding by the regulations.

It is in India's interest, activists say, that the government revise the 1970 Indian Patent Act to recognise "prior art" or existing knowledge, on which both the Indian and U.S. laws are silent. This would protect traditional wisdom in agriculture and horticulture.

"For a start, India must declare its ownership over its own biological wealth," suggests Sahai. "This must be followed with intense lobbying for institutionalizing a dispute redressal mechanism conforming to the Convention on Biological Diversity."

Vandana Shiva says that the WTO must be approached to press the U.S to change its patent laws to ensure protection against bio-piracy. "The WTO should stop the U.S. from attempting to undo the implementation of the Biodiversity Convention by countries that have ratified it. The protection of biodiversity and indigenous knowledge is an international legal obligation and this commitment needs to be upheld by all multilateral bodies."

The loopholes in the U.S. patent laws were first exposed by Mangla Rai, deputy director-general of the Indian Council for Agricultural Research, who is credited with successfully challenging a cotton patent granted to U.S. seed giant Agracetus.

"There is no doubt that their (the U.S.) patent laws are full of shortcomings which the transnationals have a penchant for exploiting," Rai told IPS. "The patent drawn on turmeric shows just how flawed the U.S. law is."

This case is reminiscent of a controversy between nongovernmental organizations (NGOs) in India and multinational corporations over patents taken on "industrial processes" related to the Neem tree (Azadirachta indica A. Juss., Meliaceae). The NGOs regard these patents as corporate theft from the Indian people. Corporations argue that they need the patents to justify the financial investments put into research and development. Most fail to recognize or compensate the centuries of unpaid, unaccounted for trial-and-error "research and development" done by the Indian people. Patent concerns are currently holding some pharmaceutical companies back from further developing drugs from artemether.

Artemether is the oral dosage form derivative of artemisinin, a Chinese herbal medicine used for treating malaria (derived from Artemisia annua L., Asteraceae). According to John Beutler, Ph.D., of the National Cancer Institute, "The folk use of turmeric constitutes prior art and thus the patent should have been disallowed. On the other hand, the neem patent is, I think, valid. What people don't seem to recognize is that the patent on neem covers a preparation/formulation of neem. It does not interfere with people's rights to use neem in any way that they choose. Monsanto's only right under the patent is to protect the specific industrial process and formulation which the patent covers. If it can be shown that the neem process is essentially a well-known method for processing neem for pesticide use, then that patent also would be invalid. Many patents are awarded which are not sustainable upon challenge. Artemether is a derivative of the natural artemisinin and should be patent able. Whether it is properly protected by patent has nothing to do with its folkloric roots."

[Aharonian, G. Internet Patent Service. Personal communication. November 29, 1996.

Anonymous. India Calls It Patent Absurdity. Business Week, August 12, 1996, p. 83.

Basant, B. 1997. IPS. New Delhi. September 4.

Beutler, J. Personal communication. May 23, 1997.

Pressman, L. M.I.T Technology Licensing Office. Personal communication. December 12, 1996.]

Article copyright American Botanical Council.


By Barbara A. Johnston and Ginger Webb